Concepedia

Khaled W. Jabboury

KW

Statistics

Publications

7

Citations

816

H-Index

7

Active since

1984

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

American University of Beirut

Khaled W. Jabboury is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, medicine, and chemotherapy.

Publications per year

1984–2017

7

Publications

7

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

, , +15

Cis-diamminedichloroplatinum (II) by 5-day continuous infusion a new dose schedule with minimal toxicity

Philip A. Salem, Maryse Khalyl, Khaled W. Jabboury et al. · Cancer · 1984 · 97 citations · Full text

, , +17

5-fluorouracil rechallenge by protracted infusion in refractory breast cancer

Khaled W. Jabboury, Frankie A. Holmes, Gabriel N. Hortobágyi · Cancer · 1989 · 49 citations

, , +13

Cell proliferation kinetics of normal and tumour tissue <i>in vitro</i>: quiescent reproductive cells and the cycling reproductive fraction

Fraser L. Baker, L. Sanger, R. W. Rodgers et al. · Cell Proliferation · 1995 · 24 citations

, , +16

Severe Nephrotoxicity: A Probable Complication of cis-Dichlorodiammineplatinum (II) and Cephalothin-Gentamicin Therapy

Philip A. Salem, Khaled W. Jabboury, Maryse F. Khalil · Oncology · 2009 · 23 citations

, , +17

1–5 of 7